KELOID REDUCTION USING TOPICAL ALLANTOIN
This invention is directed to a topical cream containing allantoin in an oil-in-water emulsion formulation. A method is provided for treating or reducing keloid formation in a patient in need thereof comprising contacting the patient's skin with an effective amount of a composition comprising allantoin in an amount from about 3.0% to about 15% by weight and a pharmaceutically acceptable excipient. In contrast to other efforts to reduce keloid formation, the present invention uses topical compositions comprising allantoin as an active pharmaceutical ingredient at higher concentrations and reduces or eliminates the occurrence of keloid formation in a shorter period of time after using the topical composition comprising allantoin.
1 . A method for treating or reducing keloid formation in a patient in need thereof comprising contacting the patient's skin with an effective amount of a composition comprising allantoin in an amount from about 3.0% to about 15% by weight and a pharmaceutically acceptable excipient.
2 . The method of claim 1 , wherein the composition is administered to the subject daily.
3 . The method of claim 1 , wherein the allantoin is in an amount of about 3.0% to about 9.0%.
4 . The method of claim 1 , wherein the allantoin is in an amount of about 3.0% to about 6.0%.
5 . The method of claim 1 , wherein the composition results in penetration of the allantoin across the skin membrane of the patient in a dose dependent manner.
6 . The method of claim 1 , wherein the composition results in penetration of the allantoin across the skin membrane of the patient without an increase in systemic blood levels of allantoin in the patient.
7 . The method of claim 1 , wherein the composition is an oil-in-water emulsion further comprising an emollient and an emulsifier.
8 . The method of claim 7 , wherein the emollient is selected from the group consisting of lanolin oil, cod liver oil, mineral oil, an alcohol, and any combination thereof.
9 . The method of claim 7 , wherein the emulsifier is selected from the group consisting of sodium laurate sulfate, a white wax, and a combination thereof.
10 . The method of claim 7 , wherein the composition further comprises a pH modifier, a solubilizing agent, an antioxidant, a preservative, a chelating agent, a viscosity agent or any combination thereof.
11 . The method of claim 10 , wherein the pH modifier is citric acid; the solubilizing agent is propylene glycol; the antioxidant is butylated hydroxytoluene (BHT); the preservative is selected from the group consisting of methylparaben, propylparaben, and a combination thereof; the chelating agent is tetrasodium EDTA; the viscosity enhancing agent is selected from the group consisting of cetyl alcohol, stearyl alcohol, and a combination thereof; and the pharmaceutically acceptable excipient is water.
12 . The method of claim 1 , wherein the pH of the composition is about 4.0 to about 5.5 at room temperature.